Reminiscence Therapy in Individuals With Dementia
Reminiscence Therapy Applied to Individuals With Dementia
1 other identifier
interventional
28
1 country
1
Brief Summary
This research will be carried out with the aim of determining the effect of reminiscence therapy applied to individuals with dementia on cognitive functions, anxiety, depression and activities of daily living. The research will be conducted with a pre-test post-test single group, quasi-experimental research design.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for not_applicable
Started Aug 2024
Shorter than P25 for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
December 13, 2023
CompletedFirst Posted
Study publicly available on registry
December 22, 2023
CompletedStudy Start
First participant enrolled
August 19, 2024
CompletedPrimary Completion
Last participant's last visit for primary outcome
October 20, 2024
CompletedStudy Completion
Last participant's last visit for all outcomes
November 20, 2024
CompletedApril 17, 2025
April 1, 2025
2 months
December 13, 2023
April 14, 2025
Conditions
Outcome Measures
Primary Outcomes (4)
Change from Baseline in Cognitive Status on the Standardized Mini Mental Test (SMMT) at Week 8
SMMT, which allows assessing cognitive status, is the most frequently used and easily applied test in dementia screening. The scale is evaluated out of 30 points in total. For SMMT, scores of 23/24 are considered the cutoff score for dementia, but traditionally scores between 24 and 30 are considered normal. A score below 24 indicates cognitive impairment, between 18 and 23 points is considered mild dementia, between 13 and 17 points is considered moderate dementia, and below 12 points is considered severe dementia. Change = (Week 8 Score-Baseline Score)
Baseline and week 8
Change from Baseline in Anxiety Symptoms on Geriatric Anxiety Scale (GAS)
GAS,developed for the elderly, is a 30-item scale that has somatic, cognitive and affective subscales and monitors anxiety symptoms. The total score on the scale varies between 0-75. A high score indicates a high level of anxiety.Change = (Week 8 Score-Baseline Score)
Baseline and week 8
Change from Baseline in Depressive Symptoms on Geriatric Depression Scale Short Form (GDS-SF)
GDS-SF, is a scale consisting of 15 questions that questions the emotional state of elderly individuals. The cut-off point of the scale is 7 points and above. Scores between 0 and 4 indicate no depressive symptoms, scores between 5 and 8 indicate mild depressive symptoms, scores between 9 and 11 indicate moderate depressive symptoms, and scores of 12 and above indicate severe depressive symptoms. Change = (Week 8 Score-Baseline Score)
Baseline and week 8
Change from Baseline in Patient's Dependency on Basic Self-Care Behaviors on Katz's Activities of Daily Living Index (KADLI)
KADLI, evaluates the patient's dependence on basic self-care behaviors that are required to live and are expected to do every day. The scale evaluates the degree of dependency in basic daily living activity parameters, including information on bathing, dressing, toileting, transfer, continence and nutrition. Scoring of the index ranges from 0 to 6, and a patient with a score of 6 is considered independent, and a patient with a score of 0 is considered fully dependent. Change = (Week 8 Score-Baseline Score)
Baseline and week 8
Study Arms (1)
Reminiscence group
EXPERIMENTALReminiscence therapies will be applied to individuals with dementia
Interventions
Reminiscence therapies will be applied to individuals with dementia in 45-minute sessions once a week for 8 weeks.
Eligibility Criteria
You may qualify if:
- Being diagnosed with mild to moderate dementia according to DSM-5 criteria (whether individuals have an official diagnosis of neurocognitive disorder according to DSM-5 criteria and their medical diagnosis will be verified from the health records at the institution),
- Getting a score between 13-23 for the educated (literate) and 10-23 for the uneducated (illiterate) on the mini mental state examination,
- Being 65 years of age or older,
- Being able to communicate,
- No vision or hearing problems,
- Consent to participate in the research.
You may not qualify if:
- Getting a score below 13 and above 23 for the educated (literate) and below 10 and above 23 for the uneducated (illiterate) from the mini mental state examination,
- Having an acute illness that prevents participation in intervention sessions,
- Having serious sensory and physical limitations that prevent participation,
- Having severe neuropsychiatric symptoms (agitation, psychosis, apathy, uncontrolled delirium, etc.),
- Having a traumatic life history,
- Having recently participated in a similar program.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Merve Çayır Yılmaz
Amasya, Turkey (Türkiye)
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Merve çayır yılmaz, asst. prof.
Amasya University
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NA
- Masking
- NONE
- Purpose
- SUPPORTIVE CARE
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
December 13, 2023
First Posted
December 22, 2023
Study Start
August 19, 2024
Primary Completion
October 20, 2024
Study Completion
November 20, 2024
Last Updated
April 17, 2025
Record last verified: 2025-04
Data Sharing
- IPD Sharing
- Will not share